Data Insights

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai) and currently in Phase I for Transitional Cell Cancer (Urothelial Cell...

Likelihood of Approval and Phase Transition Success Rate Model - IMM-47 in Transitional Cell Cancer (Urothelial Cell Cancer)

Data Insights

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for Breast Cancer: Likelihood of Approval

IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai) and currently in Phase I for Breast Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - IMM-47 in Breast Cancer

Data Insights

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for Lung Cancer: Likelihood of Approval

IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai) and currently in Phase I for Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - IMM-47 in Lung Cancer

Data Insights

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for Ovarian Cancer: Likelihood of Approval

IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai) and currently in Phase I for Ovarian Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - IMM-47 in Ovarian Cancer

Data Insights

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for Prostate Cancer: Likelihood of Approval

IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai) and currently in Phase I for Prostate Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - IMM-47 in Prostate Cancer

Data Insights

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for Colorectal Cancer: Likelihood of Approval

IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai) and currently in Phase I for Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - IMM-47 in Colorectal Cancer

Data Insights

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for Head And Neck Cancer: Likelihood of Approval

IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai) and currently in Phase I for Head And Neck Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - IMM-47 in Head And Neck Cancer

Data Insights

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for Pancreatic Cancer: Likelihood of Approval

IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai) and currently in Phase I for Pancreatic Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - IMM-47 in Pancreatic Cancer

Data Insights

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for Hepatocellular Carcinoma: Likelihood of Approval

IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai) and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - IMM-47 in Hepatocellular Carcinoma

Data Insights

IMM-47 by ImmuneOnco Biopharmaceuticals (Shanghai) for Esophageal Cancer: Likelihood of Approval

IMM-47 is under clinical development by ImmuneOnco Biopharmaceuticals (Shanghai) and currently in Phase I for Esophageal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - IMM-47 in Esophageal Cancer